FUJIFILM Holdings Corporation plans to merge Toyama Chemical, a company that conducts the research, development, manufacture, and sales of small molecule pharmaceutical products, and FUJIFILM RI Pharma Co., Ltd., a company that conducts the research, development, manufacture, and sales of radiopharmaceuticals, to form FUJIFILM Toyama Chemical Co., Ltd., in order to accelerate the development of new diagnostic and therapeutic drugs.
FUJIFILM Holdings conducts its pharmaceutical business focused on the small molecule pharmaceutical products of Toyama Chemical and the diagnostic and therapeutic radiopharmaceuticals of FUJIFILM RI Pharma. Along with the demand for responding to unmet medical needs, the practice of proper diagnoses that to optimize treatment have become increasingly important, and FUJIFILM Holdings seeks to accelerate the development of new diagnostic and therapeutic drugs and to further strengthen the relationship between “diagnosis” and “treatment” by merging Toyama Chemical and FUJIFILM RI Pharma.
The new company, FUJIFILM Toyama Chemical, will closely collaborate with FUJIFILM Corporation, which conducts research on new drugs, to develop new diagnostic and therapeutic radiopharmaceuticals and therapeutic drugs with unique mechanisms of action in the fields of oncology, central nervous system diseases, and infectious diseases, all of which have considerable unmet medical needs. The company will also promote the further development of drug delivery system (DDS) technologies that deliver the required amount of a drug to the specific area of the body on the necessary schedule. Its liposome preparation technologies and micro-needle array will be applied not only to existing drugs, but expanding to promising next-generation drugs such as nucleic acid drugs and gene therapy drugs.
The company will promote the efficient clinical development of therapeutic drugs in combination with diagnostics, increasing the accuracy and speed of the introduction of new therapies. In addition, by utilizing Fujifilm’s in vitro diagnostic (IVD) devices and reagents as well as its diagnostic drugs, the company will expand its offering of comprehensive solutions.